254 related articles for article (PubMed ID: 23260199)
21. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract][Full Text] [Related]
22. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
23. SLX4IP Promotes Telomere Maintenance in Androgen Receptor-Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization.
Mangosh TL; Awadallah WN; Grabowska MM; Taylor DJ
Mol Cancer Res; 2021 Feb; 19(2):301-316. PubMed ID: 33188147
[TBL] [Abstract][Full Text] [Related]
24. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
Gocha ARS; Harris J; Groden J
Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
[TBL] [Abstract][Full Text] [Related]
25. Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells.
Yost KE; Clatterbuck Soper SF; Walker RL; Pineda MA; Zhu YJ; Ester CD; Showman S; Roschke AV; Waterfall JJ; Meltzer PS
Sci Rep; 2019 Mar; 9(1):4544. PubMed ID: 30872698
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma.
Lee YK; Park NH; Lee H
Int J Gynecol Cancer; 2012 Mar; 22(3):434-41. PubMed ID: 22266933
[TBL] [Abstract][Full Text] [Related]
27. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
28. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
Akter J; Kamijo T
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
[TBL] [Abstract][Full Text] [Related]
29. The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.
Feng X; Luo Z; Jiang S; Li F; Han X; Hu Y; Wang D; Zhao Y; Ma W; Liu D; Huang J; Songyang Z
J Cell Sci; 2013 Sep; 126(Pt 17):3982-9. PubMed ID: 23813958
[TBL] [Abstract][Full Text] [Related]
30. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.
Wang N; Xu D; Sofiadis A; Höög A; Vukojević V; Bäckdahl M; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1571-9. PubMed ID: 24758186
[TBL] [Abstract][Full Text] [Related]
31. G-quadruplex Stabilization Fuels the ALT Pathway in ALT-positive Osteosarcoma Cells.
Amato R; Valenzuela M; Berardinelli F; Salvati E; Maresca C; Leone S; Antoccia A; Sgura A
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183119
[TBL] [Abstract][Full Text] [Related]
32. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
[TBL] [Abstract][Full Text] [Related]
33. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.
Else T; Giordano TJ; Hammer GD
J Clin Endocrinol Metab; 2008 Apr; 93(4):1442-9. PubMed ID: 18198226
[TBL] [Abstract][Full Text] [Related]
36. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
Grach AA
Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
[TBL] [Abstract][Full Text] [Related]
37. Telomere length maintenance--an ALTernative mechanism.
Royle NJ; Foxon J; Jeyapalan JN; Mendez-Bermudez A; Novo CL; Williams J; Cotton VE
Cytogenet Genome Res; 2008; 122(3-4):281-91. PubMed ID: 19188697
[TBL] [Abstract][Full Text] [Related]
38. The first molecular details of ALT in human tumor cells.
Muntoni A; Reddel RR
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R191-6. PubMed ID: 16244317
[TBL] [Abstract][Full Text] [Related]
39. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
40. Telomere maintenance in sarcomas.
Johnson JE; Broccoli D
Curr Opin Oncol; 2007 Jul; 19(4):377-82. PubMed ID: 17545803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
